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Dr. @eljko Ku}an – A Mentor of Great Impact
Dr. @eljko Ku}an became a part of my scientific educa-
tion in the fall of 1981 when as a second year Chemistry
major at PMF, I was taking a course in Biochemistry. Dr.
Ku}an was teaching it. He had recently returned to Zag-
reb after years at Rockefeller University in New York,
where he worked, among others, with Fritz Lipmann. The
course was covering the usual subjects, various metabo-
lic pathways and the like when a completely new world
suddenly opened to us; Dr. Ku}an started teaching about
recombinant DNA. It was an amazing experience as all
of us students observed how his tone of voice changed,
and his passion for the significance of the field grew. In
retrospect, we were experiencing presentations at the
highest level, by a teacher who was deeply attached to
and in a way fascinated with the subject. That was the
way Dr. Ku}an introduced molecular biology to Croatia,
by teaching a new generation a whole new discipline of
modern biology. Personally, I have shared his vision and
passion for molecular biology ever since. I feel very pri-
vileged to have been shaped in my scientific education
by Dr. Ku}an’s understanding of the importance of mo-
lecular biology.
So, where have this fundamental teacher and his tea-
chings taken my work? Indeed, I left Croatia to learn
more about molecular biology, and got my PhD in Ma-
drid. I then went on to the United States, where I have
been since 1991. I have cloned genes, characterized trans-
lational initiation factors, screened large libraries and id-
entified lead candidates for potential new drug develop-
ment. I have been a part of many sides of science, from
making and analyzing point mutations affecting the func-
tions of proteins to the »big picture« – deciding how to
create novel drugs that will help millions of people with
diabetes or chemotherapy induced anemia.
I am convinced all this would never have happened,
had Dr. Ku}an not given me excellent basic scientific
training and through his personal accounts taught us the
importance of pursuing one’s scientific instincts and true
beliefs. He taught me the importance of persistence, sci-
entific integrity, and solid scientific judgment, and most
importantly, the potential power of a single, creative mind.
Currently I hold a CSO position in a privately own-
ed biotechnology company. Our research focuses on the
modulation of cell surface receptors through a site that is
not involved in ligand binding. The challenge that we
embraced several years ago is whether the insulin recep-
tor (IR) or erythropoietin receptor (EPO-R) can be mod-
ulated (activated/deactivated) by a small molecule bind-
ing to a site on the extracellular portion of the receptor
that is not involved in the binding of the natural hormo-
ne, i.e., insulin or erythropoietin (EPO). In other words,
the question was how to achieve true hormone mimicry
from an activity standpoint, without competing/altering
the binding of a natural hormone.
As a student in Dr. Ku}an’s laboratory, I worked on
tRNA molecules and their respective synthetases. Al-
though I left that field many years ago, the principles
that I observed and learned at that time had an impact on
my scientific thinking and resulted in the collaborative
development of what has turned out to be a novel propri-
etary technology for the modulation (activation/deacti-
vation) of receptor activity. The general idea of protein-
protein interactions, and how conformational changes
induced in a small (two to three amino acids) functional
region can completely alter protein activity was success-
fully applied to the system of growth factor receptors
and their ligands.
Erythropoiesis (red blood cell formation) is regulat-
ed by a number of growth factors and cytokines, among
which EPO plays an essential role. Its effect on survival,
proliferation and differentiation of erythroid progenitor
cells depends on the signal emanating from EPO-R. The
crystal structure of the erythropoietin receptor (EPO-R)
revealed that the receptor exists as a preformed dimer,
with a geometry different from that of the erythropoie-
tin-bound receptor, indicating that EPO activates the re-
ceptor by changing the conformation of a pre-existing
dimer. Binding of EPO triggers a conformational change
in the receptor, bringing the two receptor chains closer
together, forming a short-distance contact interface be-
tween receptor chains. Receptor-ligand interaction and
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the assumed geometry of the hormone-receptor complex
has served as general guidance in hormone mimicry re-
search. The assumed sequence of events in EPO-R acti-
vation by EPO and its size (35 kDa protein) have been
major challenges in attempts to design a small molecule
mimic of EPO. Many programs failed because their ma-
jor focus was a replacement of EPO by molecules bind-
ing into the same site.
We have taken a different approach. It is based on
the idea that once you determine the site on the receptor
that undergoes conformational change as a consequence
of the hormone binding, it is possible to induce the same
conformational change by binding a small molecule to
this site, and thus bring the receptors into the proximity
required for the activation of signaling events. The ap-
proach relies on the concept that an evolutionary con-
served, receptor specific, dimerization domain (or pro-
tein-protein interaction interface) exists in many, if not
most, receptors. Identification of such functional sites on
a number of growth factor receptors has led to the devel-
opment of our platform technology. As for the problem
of EPO mimicry, a small molecule was identified that
binds to the receptor interface region and activates the
EPO-R signaling pathway. It directly causes a conforma-
tional change in the receptor interface that is similar to
the change that occurs as a consequence of EPO binding
to the N-terminal portion of the receptor.
From the scientific standpoint, this is a significant
break-through. It is a novel idea of how receptor activity
can be modulated. More importantly, from a patient’s
standpoint, this means that tablets taken orally can be
developed to replace drugs currently available only as
injectable hormones like insulin or EPO.
Today, I live far away from Zagreb and my scienti-
fic work does not involve protein synthesis – but through
all these years I have followed the principles and general
rules governing biological processes that I was taught by
Dr. Ku}an. I know that I am just one of the students, fri-
ends and colleagues who was inspired and deeply influ-
enced by Dr. Ku}an during sharp-witted discussions in
the laboratory, and relaxed conversations over a glass of
wine. For the years to come I wish him further indefati-
gable enthusiasm in science and I am most grateful for
his fundamental influence on my own scientific life.
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